 | |
Vanguard Health Care Fund | VGHCXMutual Fund | |
| Vanguard Health Care Fund | |
| Last update 2024-08-02 | 95 Stocks (7 new) |
| Value $46.52 Bil | Turnover 6 % |
| Portfolio Report | |
Vanguard Health Care Fund Profile
Founded in 1928, Wellington Management Company LLP is among the nation’s oldest and most respected institutional investment managers. The firm has advised Vanguard Health Care Fund since 1984. Fund Manager: Jean M. Hynes, CFA, CEO of Wellington Management Company, Managing Partner and Equity Portfolio Manager.
Vanguard Health Care Fund Investing Philosophy
The Vanguard Health Care Fund seeks long-term capital appreciation by investing in stocks broadly representing the health care industry. The advisor seeks to maintain exposure across five primary subsectors: health services, medical products, specialty pharmaceuticals, major pharmaceuticals and international markets.
Fundamental research focuses on companies with high-quality balance sheets, strong management and the potential for new products that will lead to above-average growth in revenue and earnings. Reflecting the advisor’s contrarian style, stocks may be purchased after negative events have caused a decline in share price.
Fundamental research focuses on companies with high-quality balance sheets, strong management and the potential for new products that will lead to above-average growth in revenue and earnings. Reflecting the advisor’s contrarian style, stocks may be purchased after negative events have caused a decline in share price.
Vanguard Health Care Fund's Portfolio
Vanguard Health Care Fund Current Holdings
| Ticker |
|---|
| Ticker |
TSE:4503 |
GH |
PACS |
CRNX |
RNA |
INSM |
MRUS |
APGE |
ISRG |
CYTK |
EXAS |
MORF |
AUTL |
NVO |
HKSE:09688 |
XSWX:GALD |
ALGN |
LSE:GSK |
IMCR |
GPCR |
| Ticker | | Company | Shares | Value ($1000) | Shares Change % | Weighting % | Trade Impact % | % of Shares outstanding | 3M Change % | YTD Change % | Market Cap $Mil | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | | Company | Shares | Value ($1000) | Shares Change % | Weighting % | Trade Impact % | % of Shares outstanding | 3M Change % | YTD Change % | Market Cap $Mil | Industry |
TSE:4503 | Astellas Pharma Inc | 19,888,786 | 196217.550 | New Holding | 0.420 | +0.42% | 1.110 | +11.89% | +2.29% | 3023073.792 | Drug Manufacturers | |
GH | Guardant Health Inc | 2,690,435 | 77699.760 | New Holding | 0.170 | +0.17% | 2.200 | -16.13% | -7.17% | 3073.091 | Medical Diagnostics & Research | |
PACS | PACS Group Inc | 2,322,171 | 68504.050 | New Holding | 0.150 | +0.15% | 1.520 | +38.57% | 0% | 6365.380 | Healthcare Providers & Services | |
CRNX | Crinetics Pharmaceuticals Inc | 960,171 | 43006.060 | New Holding | 0.090 | +0.09% | 1.220 | +18.09% | +46.99% | 4181.463 | Biotechnology | |
RNA | Avidity Biosciences Inc | 733,400 | 29959.390 | New Holding | 0.060 | +0.06% | 0.680 | +17.14% | +396.13% | 5279.678 | Biotechnology | |
INSM | Insmed Inc | 227,800 | 15262.600 | New Holding | 0.030 | +0.03% | 0.140 | +11.44% | +135.83% | 12566.467 | Biotechnology | |
MRUS | Merus NV | 248,400 | 14697.830 | New Holding | 0.030 | +0.03% | 0.370 | -8.70% | +80.07% | 3376.417 | Biotechnology | |
APGE | Apogee Therapeutics Inc | 1,569,000 | 61740.150 | +183.90% | 0.130 | +0.08% | 2.780 | +39.70% | +81.85% | 2890.729 | Biotechnology | |
ISRG | Intuitive Surgical Inc | 1,675,518 | 745354.180 | +178.68% | 1.600 | +1.03% | 0.470 | +11.27% | +43.48% | 172044.726 | Medical Devices & Instruments | |
CYTK | Cytokinetics Inc | 4,067,922 | 220400.010 | +176.81% | 0.470 | +0.30% | 3.470 | +6.48% | -33.76% | 6574.818 | Biotechnology | |
EXAS | Exact Sciences Corp | 5,033,812 | 212678.560 | +89.44% | 0.460 | +0.22% | 2.730 | +63.98% | -7.08% | 12660.432 | Medical Diagnostics & Research | |
MORF | Morphic Holding Inc | 3,618,064 | 123267.440 | +87.75% | 0.260 | +0.12% | 7.200 | +88.50% | +97.32% | 2862.305 | Biotechnology | |
AUTL | Autolus Therapeutics PLC | 13,541,015 | 47122.730 | +85.52% | 0.100 | +0.05% | 5.090 | -1.15% | -40.14% | 1043.117 | Biotechnology | |
NVO | Novo Nordisk A/S | 11,095,414 | 1587584.590 | +78.79% | 3.410 | +1.50% | 0.250 | -5.85% | +29.07% | 587823.781 | Biotechnology | |
HKSE:09688 | Zai Lab Ltd | 29,739,200 | 50655.820 | +75.80% | 0.110 | +0.05% | 3.000 | +10.87% | -24.09% | 16256.151 | Biotechnology | |
XSWX:GALD | Galderma Group AG | 3,260,599 | 269012.550 | +43.71% | 0.580 | +0.18% | 1.370 | +9.27% | 0% | 19014.817 | Drug Manufacturers | |
ALGN | Align Technology Inc | 853,031 | 205947.270 | +34.34% | 0.440 | +0.11% | 1.130 | +4.06% | -8.02% | 18839.347 | Medical Devices & Instruments | |
LSE:GSK | GSK PLC | 36,708,771 | 706064.200 | +33.74% | 1.520 | +0.38% | 0.900 | +1.55% | +14.07% | 65650.879 | Drug Manufacturers | |
IMCR | Immunocore Holdings PLC | 3,849,028 | 130443.560 | +32.84% | 0.280 | +0.07% | 7.700 | -5.82% | -50.45% | 1691.637 | Biotechnology | |
GPCR | Structure Therapeutics Inc | 3,827,945 | 150323.400 | +29.63% | 0.320 | +0.07% | 6.710 | -19.93% | -6.65% | 2177.469 | Biotechnology |
Total 105
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers